Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

day and thank you for standing by. Welcome to the Nanobiotics Full Year 2025 Financial Results Conference Core. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1, 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Joanne Choi, Head of Investor Relations U.S. Please go ahead. Thank you, Heidi. Good afternoon and good morning. And welcome to the Nanobiotics Conference Call to discuss our full year 2025 financial and operational results. Joining me on the call today are Laurent Levy, co-founder and chief executive officer, and Bart Van Ryn, chief financial and business officer. Today's call is being webcast and will be available on our website for replay. Before we begin, I would like to remind you that today's discussion will include four looking statements within the meaning of applicable securities laws. These statements are based on our current expectations, assumptions, and available information and are subject to significant risks and uncertainties that could cause actual results to differ materially. Such risks include, among others, those related to the timing, progress, and outcomes of our research and clinical development programs, regulatory developments, and our financial and operational performance. We encourage you to review the full description of risk factors that can be found in the documents we filed with the AMF in France and the SEC in the U.S. which are available on the inves...